Insomnia Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Insomnia is a sleep disorder that is characterized by difficulty falling and/or staying asleep. Symptoms include difficulty falling asleep at night, irritability, depression or anxiety, tension headaches, and distress in the stomach and intestines. Risk factors include age, mental health disorders, stress, and shift working.
The Insomnia pipeline drugs market research report provides comprehensive information on the therapeutics under development for Insomnia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history, and the latest news and press releases. Additionally, the report offers an overview of key players involved in therapeutic development for Insomnia and features dormant and discontinued projects.
Insomnia Pipeline Drugs Market Segmentation by Targets
Some of the targets of the Insomnia pipeline drugs market are Orexin Receptor Type 2, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Orexin Receptor Type 1, Melatonin Receptor Type 1A, Melatonin Receptor Type 1B, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1, and Gamma-Aminobutyric Acid Type A Receptor Subunit.
Insomnia Pipeline Drugs Market Analysis, by Targets
For more Insomnia pipeline drugs market target insights, download a free report sample
Insomnia Pipeline Drugs Market Segmentation by Mechanism of Actions
Some of the mechanisms of action of the Insomnia pipeline drugs market are Orexin Receptor Type 2 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Orexin Receptor Type 1 Antagonist, Melatonin Receptor Type 1A Agonist, Melatonin Receptor Type 1B Agonist, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1 Agonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit Agonist.
Insomnia Pipeline Drugs Market Analysis, by Mechanism of Actions
For more mechanism of action insights into the Insomnia pipeline drugs market, download a free report sample
Insomnia Pipeline Drugs Market Segmentation by Routes of Administration
The key routes of administration in the Insomnia pipeline drugs market are oral, sublingual, intravenous, nasal, transdermal, buccal, inhalational, and parenteral.
Insomnia Pipeline Drugs Market Analysis, by Routes of Administration
For more routes of administration insights into the Insomnia pipeline drugs market, download a free report sample
Insomnia Pipeline Drugs Market Segmentation by Molecule Types
The molecule types in the Insomnia pipeline drugs market are Small Molecule and Biologic.
Insomnia Pipeline Drugs Market Analysis, by Molecule Types
For more molecule type insights into the Insomnia pipeline drugs market, download a free report sample
Competitive Landscape
Some of the key companies in the Insomnia pipeline drugs market are Idorsia Pharmaceutical Ltd, Taisho Pharmaceutical Holdings Co Ltd, Zelira Therapeutics Ltd, Evotec SE, Imbrium Therapeutics LP, Johnson & Johnson, and Acahealth Pharma and Biotech Co Ltd.
Insomnia Pipeline Drugs Market Analysis, by Companies
To know more about the Insomnia pipeline drugs market companies, download a free report sample
Insomnia Pipeline Drugs Market Report Overview
| Key Targets | Orexin Receptor Type 2, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Orexin Receptor Type 1, Melatonin Receptor Type 1A, Melatonin Receptor Type 1B, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1, and Gamma-Aminobutyric Acid Type A Receptor Subunit |
| Key Mechanism of Actions | Orexin Receptor Type 2 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Orexin Receptor Type 1 Antagonist, Melatonin Receptor Type 1A Agonist, Melatonin Receptor Type 1B Agonist, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1 Agonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit Agonist |
| Key Routes of Administration | Oral, Sublingual, Intravenous, Nasal, Transdermal, Buccal, Inhalational, and Parenteral |
| Key Molecule Types | Small Molecule and Biologic |
| Key Companies | Idorsia Pharmaceutical Ltd, Taisho Pharmaceutical Holdings Co Ltd, Zelira Therapeutics Ltd, Evotec SE, Imbrium Therapeutics LP, Johnson & Johnson, and Acahealth Pharma and Biotech Co Ltd |
Scope
This report provides:
- A snapshot of the global therapeutic landscape of Insomnia.
- Reviews of pipeline therapeutics for Insomnia by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Pipeline products based on several stages of development ranging from pre-registration to discovery and undisclosed stages.
- Descriptive drug profiles for the pipeline products which comprise product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- Reviews key companies involved in Insomnia therapeutics and enlists all their major and minor projects.
- Evaluation of Insomnia therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA), and molecule type.
- All the dormant and discontinued pipeline projects.
- Reviews of the latest news related to pipeline therapeutics for Insomnia.
Reasons to Buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with a potentially strong product portfolio and create effective counterstrategies to gain a competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Insomnia.
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and their most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Insomnia pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from the pipeline.
Key Players
Table of Contents
List of Tables
List of Figures
Frequently Asked Questions
Some of the key targets of the Insomnia pipeline drugs market are the Orexin Receptor Type 2, Cannabinoid Receptor 1, Cannabinoid Receptor 2, Orexin Receptor Type 1, Melatonin Receptor Type 1A, Melatonin Receptor Type 1B, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1, and Gamma-Aminobutyric Acid Type A Receptor Subunit.
Some of the key mechanisms of action in the Insomnia pipeline drugs market are Orexin Receptor Type 2 Antagonist, Cannabinoid Receptor 1 Agonist, Cannabinoid Receptor 2 Agonist, Orexin Receptor Type 1 Antagonist, Melatonin Receptor Type 1A Agonist, Melatonin Receptor Type 1B Agonist, Gamma-Aminobutyric Acid Receptor Subunit Alpha 1 Agonist, and Gamma-Aminobutyric Acid Type A Receptor Subunit Agonist.
The key routes of administration in the Insomnia pipeline drugs market are oral, sublingual, intravenous, nasal, transdermal, buccal, inhalational, and parenteral.
The molecule types in the Insomnia pipeline drugs market are Small Molecule and Biologic.
Some of the key companies in the Insomnia pipeline drugs market are Idorsia Pharmaceutical Ltd, Taisho Pharmaceutical Holdings Co Ltd, Zelira Therapeutics Ltd, Evotec SE, Imbrium Therapeutics LP, Johnson & Johnson, and Acahealth Pharma and Biotech Co Ltd.
Get in touch to find out about our multi-purchase discounts
reportstore@globaldata.com
Tel +44 (0) 20 7947 2960
Every customer’s requirement is unique. We understand that and can customize the report basis your exact research requirements pertaining to market insights, innovation insights, strategy and planning, and competitive intelligence. You can also avail the option of purchasing stand-alone sections of the report or request for a country specific report.
Testimonial
“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.
GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”
“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”
Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.
Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.
